2019;2(9):e1910593. doi:10.1001/jamanetworkopen.2019.10593 Key Points Question What proportion of National Cancer Institute–sponsored, phase 3 Clinical Trial Network program studies are associated with guideline care or new drug indications? Findings In this cohort study based on 182 trials includi...
Through a physician-in-the-loop process, this tool enables the personalised adaptation of drug therapy in cancer. The general trend is that rule-based decision-making is over time substituted for machine/deep learning-based approaches, as more data is gathered, from on-market use and from ...
CLINICAL drug trialsUNITED States. Food & Drug AdministrationINVESTIGATIONAL drugsDISEASESHUMAN beingsTesting novel drugs on fellow human beings is fraught with potential ethical concerns; however, developing drugs to treat the wide spectrum of human diseases and disorders is also a moral imperative. How...
Nat. Rev. Drug Discov. 17, 547–558 (2018). CAS PubMed PubMed Central Google Scholar Shultz, M. D. Two decades under the influence of the rule of five and the changing properties of approved oral drugs. J. Med. Chem. 62, 1701–1714 (2019). CAS PubMed Google Scholar Rainsford,...
SHANGHAI, July 21 (Xinhua) -- Chinese scientists will conduct the second-phase clinical trial of a new drug to treat lupus, an autoimmune disease, the Chinese Academy of Sciences (CAS) said. The new drug SM934 is a water-soluble artemisinin derivative developed by researchers with the Shang...
As of the 23rd of July, 2020; there are 32 studies registered on clinicaltrials.gov to assess the utility of this drug in the management of COVID-19 (3 completed, 12 recruiting).1 Pharmacology Favipiravir (T-705) is a synthetic prodrug, first discovered while assessing the antiviral ...
DALLAS, Dec. 11, 2019 /PRNewswire/ -- Vision Impact Institute: New Reports on State of Vision Will Renew Global Focus on the Societal Impact of Poor Vision
“We are pleased with the FDA’s assessment of the sufficiency of the efficacy and safety data from one Phase 3 clinical trial to support an NDA filing,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus. “We remain on track to submit the NDA for use of ganaxolone in ...
(Becton, Dickinson and Company – BD Diagnostic Systems, Heidelberg, Germany) plus 0.5% yeast extract (Carl Roth GmbH & Co. KG, Karlsruhe, Germany) and 1.5% agar (TSAYE) was used. Another aspect was to rule out inhibition by hydrogen peroxide (H2O2) by incubating the test plates under ...
SK Biopharmaceuticals, which targets the U.S. market with its epilepsy treatment, Cenobamate (XCopri in the U.S.), is stepping up the development of follow-up products.The Ministry of Food and Drug Safety approved the phase 3 clinical trial of SK Biophar